Clinical pharmacology, pharmacokinetics, and hemodynamic effects of nicardipine.

[1]  C. Lambert,et al.  Effects of nicardipine on coronary blood flow. , 1988, American heart journal.

[2]  M. Gheorghiade,et al.  Acute and chronic hemodynamic effects of nicardipine hydrochloride in patients with heart failure. , 1987, American heart journal.

[3]  J. Hill,et al.  Effect of nicardipine on determinants of myocardial ischemia occurring during acute coronary occlusion produced by percutaneous transluminal coronary angioplasty. , 1987, The American journal of cardiology.

[4]  C. Hanet,et al.  Myocardial protection by intracoronary nicardipine administration during percutaneous transluminal coronary angioplasty. , 1987, The American journal of cardiology.

[5]  S. Clissold,et al.  Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. , 1987, Drugs.

[6]  P. Rocha,et al.  Acute hemodynamic effects of intravenous nicardipine in patients treated chronically with propranolol for coronary artery disease. , 1987, The American journal of cardiology.

[7]  C. Hanet,et al.  Effects of nicardipine on myocardial metabolism and coronary haemodynamics: A review , 1986 .

[8]  S. Taylor,et al.  Haemodynamic analysis of the effects of nicardipine and metoprolol alone and in combination in coronary artery disease. , 1985, European heart journal.

[9]  J. Hill,et al.  Coronary and systemic hemodynamic effects of nicardipine. , 1985, The American journal of cardiology.

[10]  M. Gaab,et al.  Intracranial effects of nicardipine. , 1985, British journal of clinical pharmacology.

[11]  D. J. Graham,et al.  The metabolism and pharmacokinetics of nicardipine hydrochloride in man. , 1985, British journal of clinical pharmacology.

[12]  T. Takenaka,et al.  Cardiovascular pharmacology of nicardipine in animals. , 1985, British journal of clinical pharmacology.

[13]  B. J. Alps,et al.  Nicardipine in models of myocardial infarction. , 1985, British journal of clinical pharmacology.

[14]  R. Dow,et al.  The effect of nicardipine on pituitary hormone release in normal volunteers. , 1985, British journal of clinical pharmacology.

[15]  R. Dow,et al.  The effect of nicardipine on glucose and drug-stimulated insulin secretion in normal volunteers. , 1985, British journal of clinical pharmacology.

[16]  J. Reid,et al.  Effects of nicardipine on aldosterone release and pressor mechanisms. , 1985, British journal of clinical pharmacology.

[17]  R. Hené,et al.  Influence of nicardipine on blood pressure, renal function and plasma aldosterone in normotensive volunteers. , 1985, British journal of clinical pharmacology.

[18]  W. Hillis,et al.  Noninvasive assessment of the haemodynamic effects of nicardipine in normotensive subjects. , 1985, British journal of clinical pharmacology.

[19]  K. Nademanee,et al.  Second-generation calcium antagonists: search for greater selectivity and versatility. , 1985, The American journal of cardiology.

[20]  D J Triggle,et al.  New developments in Ca2+ channel antagonists. , 1984, Journal of medicinal chemistry.

[21]  R. Jedeikin,et al.  Spontaneous rupture of distal oesophagus (Boerhaave's syndrome) with unusual clinical presentation of pneumoperitoneum. , 1984, Postgraduate medical journal.

[22]  D. J. Triggle,et al.  New developments in calcium ion channel antagonists , 1983 .

[23]  K. Nademanee,et al.  Electrophysiologic and hemodynamic effects of slow-channel blocking drugs. , 1982, Progress in cardiovascular diseases.

[24]  S. Higuchi,et al.  Application of the stable isotope technique to the elucidation of the saturation phenomenon of nicardipine hydrochloride metabolizing enzyme activity in dogs. , 1980, Biomedical mass spectrometry.

[25]  T. Seki,et al.  Pharmacological evaluation of YC-93, a new vasodilator, in healthy volunteers. , 1977, International journal of clinical pharmacology and biopharmacy.

[26]  E. Raftery,et al.  Intravenous nicardipine in patients with chronic heart failure: a nuclear stethoscope study. , 1984, Postgraduate medical journal.

[27]  S. Taylor,et al.  Haemodynamic effects of nicardipine in acute myocardial infarction. , 1984, Postgraduate medical journal.

[28]  L. Brasseur,et al.  Effects of nicardipine or nifedipine added to propranolol in patients with coronary artery disease. , 1984, Postgraduate medical journal.

[29]  H. Nakaya,et al.  Effects of nicardipine, a new dihydropyridine vasodilator, on coronary circulation and ischemia-induced conduction delay in dogs. , 1982, Arzneimittel-Forschung.

[30]  S. Higuchi,et al.  Metabolic fate of nicardipine hydrochloride, a new vasodilator, by various species in vitro. , 1980, Xenobiotica; the fate of foreign compounds in biological systems.

[31]  S. Higuchi,et al.  Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species. , 1980, Xenobiotica; the fate of foreign compounds in biological systems.

[32]  S. Higuchi,et al.  Pharmacokinetic studies on nicardipine hydrochloride, a new vasodilator, after repeated administration to rats, dogs and humans. , 1980, Xenobiotica; the fate of foreign compounds in biological systems.

[33]  S. Higuchi,et al.  Absorption, excretion and metabolism of a new dihydropyridine diester cerebral vasodilator in rats and dogs. , 1977, Xenobiotica; the fate of foreign compounds in biological systems.

[34]  A. Fleckenstein.  Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. , 1977, Annual review of pharmacology and toxicology.